Results 151 to 160 of about 347,846 (181)

Using partially shared radiomics features to simultaneously identify isocitrate dehydrogenase mutation status and epilepsy in glioma patients from MRI images. [PDF]

Sci Rep
Wang Y, Gao A, Yang H, Bai J, Zhao G, Zhang H, Song Y, Wang C, Zhang Y, Cheng J, Yang G.   +10 more
europepmc   +1 more source

Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives. [PDF]

Cancers (Basel)
Carosi F, Broseghini E, Fabbri L, Corradi G, Gili R, Forte V, Roncarati R, Filippini DM, Ferracin M.   +8 more
europepmc   +1 more source

Diagnosis of Isocitrate Dehydrogenase-Mutant Astrocytoma in the Subcallosal Gyrus Using T2-Fluid-Attenuated Inversion Recovery Mismatch Sign and Quantitative Magnetic Resonance Relaxometry. [PDF]

Cureus
Tajima Y, Yuzawa S, Kanemura Y, Tanino M, Kinoshita M.   +4 more
europepmc   +1 more source

Molecular diversity in isocitrate dehydrogenase-wild-type glioblastoma. [PDF]

Brain Commun
Fares J, Wan Y, Mair R, Price SJ.
europepmc   +1 more source

State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond. [PDF]

Am Soc Clin Oncol Educ Book
Schaff LR, Ioannou M, Geurts M, van den Bent MJ, Mellinghoff IK, Schreck KC.   +5 more
europepmc   +1 more source

Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia. [PDF]

Leukemia
Fruchtman H, Avigan ZM, Waksal JA, Brennan N, Mascarenhas JO.   +4 more
europepmc   +1 more source

Preparation and Preclinical Evaluation of ¹⁸F-Labeled Olutasidenib Derivatives for Non-Invasive Detection of Mutated Isocitrate Dehydrogenase 1 (mIDH1). [PDF]

Molecules
Cologni R, Holschbach M, Schneider D, Bier D, Schulze A, Stegmayr C, Endepols H, Ermert J, Neumaier F, Neumaier B.   +9 more
europepmc   +1 more source

Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma. [PDF]

Acta Neuropathol
Weller M, Felsberg J, Hentschel B, Gramatzki D, Kubon N, Wolter M, Reusche M, Roth P, Krex D, Herrlinger U, Westphal M, Tonn JC, Regli L, Maurage CA, von Deimling A, Pietsch T, Le Rhun E, Reifenberger G.   +17 more
europepmc   +1 more source

Blood group O attributes to prolonged progression-free survival, overall survival, and 5-year survival in isocitrate dehydrogenase-wildtype glioblastoma patients with MGMT promoter methylation. [PDF]

Neurooncol Adv
Wiewrodt R, Kloss M, Jost-Engl J, Troschel FM, Troschel BO, Eich HT, Thomas C, Lemcke L, Stummer W, Wiewrodt D.   +9 more
europepmc   +1 more source

Correction: A positive feedback inhibition of isocitrate dehydrogenase 3β on paired-box gene 6 promotes Alzheimer-like pathology. [PDF]

Signal Transduct Target Ther
Wang X, Liu Q, Yu HT, Xie JZ, Zhao JN, Fang ZT, Qu M, Zhang Y, Yang Y, Wang JZ.   +9 more
europepmc   +1 more source